Neoplastic and non‐neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance
dc.contributor.author | Goebel, Teresa E. | en_US |
dc.contributor.author | Schiltz, Nicholas K. | en_US |
dc.contributor.author | Woodside, Kenneth J. | en_US |
dc.contributor.author | Chandran Pillai, Aiswarya | en_US |
dc.contributor.author | Caimi, Paolo F. | en_US |
dc.contributor.author | Lazarus, Hillard M. | en_US |
dc.contributor.author | Koroukian, Siran M. | en_US |
dc.contributor.author | Campagnaro, Erica L. | en_US |
dc.date.accessioned | 2015-10-07T20:43:20Z | |
dc.date.available | 2016-10-10T14:50:23Z | en |
dc.date.issued | 2015-09 | en_US |
dc.identifier.citation | Goebel, Teresa E.; Schiltz, Nicholas K.; Woodside, Kenneth J.; Chandran Pillai, Aiswarya; Caimi, Paolo F.; Lazarus, Hillard M.; Koroukian, Siran M.; Campagnaro, Erica L. (2015). "Neoplastic and non‐neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance." Clinical Transplantation 29(9): 851-857. | en_US |
dc.identifier.issn | 0902-0063 | en_US |
dc.identifier.issn | 1399-0012 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/113779 | |
dc.description.abstract | Monoclonal gammopathy of undetermined significance (MGUS) occurs in 3–7% of the elderly population, with higher prevalence in renal failure patients, and is associated with a 25‐fold increased lifetime risk for plasma cell myeloma (PCM), also known as multiple myeloma. Using the California State Inpatient, Emergency Department, and Ambulatory Surgery Databases components of the Healthcare Cost and Utilization Project (HCUP), we sought to determine whether patients with MGUS who undergo solid organ allograft (n = 22 062) are at increased adjusted relative risk (aRR) for hematologic malignancy and other complications. Among solid organ transplant patients, patients with preexisting MGUS had higher aRR of PCM (aRR 19.46; 95% CI 7.05, 53.73; p < 0.001), venous thromboembolic events (aRR 1.66; 95% CI 1.15, 2.41; p = 0.007), and infection (aRR 1.24; 95% CI 1.06, 1.45; p = 0.007). However, when comparing MGUS patients with and without solid organ transplant, there was decreased aRR for PCM with transplant (aRR 0.34; 95% CI 0.13, 0.88; p = 0.027), and increased venous thromboembolic events (aRR 2.33; 95% CI 1.58, 3.44; p < 0.001) and infectious risks (aRR 1.44; 95% CI 1.23, 1.70; p < 0.001). While MGUS increased the risk of PCM overall following solid organ transplantation, there was lower risk of PCM development compared to MGUS patients who did not receive a transplant. MGUS should not preclude solid organ transplant. | en_US |
dc.publisher | Agency for Healthcare Research and Quality | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Healthcare Cost and Utilization Project | en_US |
dc.subject.other | monoclonal gammopathy of undetermined significance | en_US |
dc.subject.other | multiple myeloma | en_US |
dc.subject.other | plasma cell myeloma | en_US |
dc.subject.other | post‐transplant lymphoproliferative disorder | en_US |
dc.subject.other | solid organ transplantation | en_US |
dc.subject.other | venous thromboembolism | en_US |
dc.title | Neoplastic and non‐neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/113779/1/ctr12595_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/113779/2/ctr12595.pdf | |
dc.identifier.doi | 10.1111/ctr.12595 | en_US |
dc.identifier.source | Clinical Transplantation | en_US |
dc.identifier.citedreference | Massie AB, Kuricka LM, Segev DL. Big data in organ transplantation: registries and administrative claims. Am J Transplant 2014: 14: 1723. | en_US |
dc.identifier.citedreference | Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004: 15: 1490. | en_US |
dc.identifier.citedreference | Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke‐Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004: 101: 558. | en_US |
dc.identifier.citedreference | Kristinsson SY, Fears TR, Gridley G et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008: 112: 3582. | en_US |
dc.identifier.citedreference | Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. Clin Adv Hematol Oncol 2009: 7: 827. | en_US |
dc.identifier.citedreference | Kristinsson SY, Pfeiffer RM, Björkholm M et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population‐based study. Blood 2010: 115: 4991. | en_US |
dc.identifier.citedreference | Gregersen H, Nørgaard M, Severinsen MT, Engebjerg MC, Jensen P, Sørensen HT. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol 2011: 86: 129. | en_US |
dc.identifier.citedreference | Za T, De Stefano V, Rossi E et al. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. Br J Haematol 2013: 160: 673. | en_US |
dc.identifier.citedreference | Kristensson SY, Tang M, Pfeiffer RM et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures; a population‐based study. Blood 2010: 116: 2651. | en_US |
dc.identifier.citedreference | Soltero L, Carbajal H, Xu J et al. Initial survival data of kidney transplant patients with pre‐transplant monoclonal gammopathy. Clin Transplant 2012: 26: 300. | en_US |
dc.identifier.citedreference | Giordano M, Santangelo L, Scarasciulli ML et al. Monoclonal gammopathy of undetermined significance in pediatric kidney transplantation: a possible role of Epstein‐Barr virus. Pediatr Transplant 2014: 18: 42. | en_US |
dc.identifier.citedreference | Naina HV, Harris S, Dispenzieri A et al. Long‐term follow‐up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Am J Nephrol 2012: 35: 365. | en_US |
dc.identifier.citedreference | HCUP Central Distributor SID Availability of Data Elements – 2009. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality, 2010. www.hcup-us.ahrq.gov/db/state/siddist/siddistvarnote2009.jsp (accessed July 3, 2015). | en_US |
dc.identifier.citedreference | Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004: 159: 702. | en_US |
dc.identifier.citedreference | Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011: 46: 399. | en_US |
dc.identifier.citedreference | Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983: 70: 41. | en_US |
dc.identifier.citedreference | Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998: 36: 8. | en_US |
dc.identifier.citedreference | Kasiske BL, Kukla A, Thomas D et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims‐based diagnoses. Am J Kidney Dis 2011: 58: 971. | en_US |
dc.identifier.citedreference | Safadi S, Dispenzieri A, Amer H et al. Multiple myeloma after kidney transplantation. Clin Transplant 2015: 29: 76. | en_US |
dc.identifier.citedreference | Jimenez‐Zepeda VH, Heilman RL, Engel RA et al. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation 2011: 92: 570. | en_US |
dc.identifier.citedreference | Rostaing L, Modesto A, Abbal M, Durand D. Long‐term follow up of monoclonal gammopathy of undetermined significance in transplant patients. Am J Nephrol 1994: 14: 187. | en_US |
dc.identifier.citedreference | Galioto A, Morando F, Rosi S et al. Monoclonal gammopathy after liver transplantation: a risk factor for long‐term medical complications other than malignancies. Transpl Int 2012: 25: 25. | en_US |
dc.identifier.citedreference | Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008: 111: 3388. | en_US |
dc.identifier.citedreference | Gale RP, Eapen M, Logan B, Zhang M‐J, Lazarus HM. Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? Bone Marrow Transplant 2009: 43: 435. | en_US |
dc.identifier.citedreference | Gale RP, Lazarus HM. How helpful are meta‐analyses in determining the best therapy of blood diseases? Acta Haematol 2011: 125: 91. | en_US |
dc.identifier.citedreference | Rajkumar SV, Kyle RA, Therneau TM et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005: 106: 812. | en_US |
dc.identifier.citedreference | Leung N, Bridoux F, Hutchinson CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012: 120: 4292. | en_US |
dc.identifier.citedreference | National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER hematopoietic and lymphoid neoplasm database. URL: seer.cancer.gov/seertools/hemelymph (accessed April 22, 2015). | en_US |
dc.identifier.citedreference | Centers for Medicare & Medicaid Services. ICD‐9‐CM diagnosis and procedure codes: abbreviated and full code titles. URL: www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosisCodes/codes.html (accessed April 22, 2015). | en_US |
dc.identifier.citedreference | Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006: 354: 1362. | en_US |
dc.identifier.citedreference | Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009: 113: 5418. | en_US |
dc.identifier.citedreference | Kyle RA, Therneau TM, Rajkumar SV et al. A long‐term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002: 346: 564. | en_US |
dc.identifier.citedreference | Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003: 194: 112. | en_US |
dc.identifier.citedreference | Bida JP, Kyle RA, Therneau TM et al. Disease associations with monoclonal gammopathy of undetermined significance: a population‐based study of 17 398 patients. Mayo Clin Proc 2009: 84: 685. | en_US |
dc.identifier.citedreference | Kristinsson SY, Bjorkhom M, Andersson TM et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population‐based study. Haematologica 2009: 94: 1714. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.